ERBB2 and breast carcinoma: A peptide-based vaccine utilizing the E75 peptide (HER-2/neu369-377), also known as nelipepimut-S or NeuVax, was coadministered with GM-CSF in phases I and II trials, and production of antigen-specific CD8+ T cells was enhanced, leading to progression-free survival in breast cancer patients expressing HLA-A2 and HLA-A3 molecules [93].